Tulane University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: New Orleans LA United States (1834)

Organization Overview

First Clinical Trial
1992
NCT00000134
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Donald Krogstad | Institute for Clinical Effectiveness and Health Policy | Jing Chen | Jodi Layton, MD | Nakhle Saba, MD | Tulane | Tulane Department of Dermatology | Tulane Medical Center | Tulane School of Medicine | Tulane School of Public Health and Tropical Medicine | Tulane Univeristy | Tulane University | Tulane University Health Sciences Center | Tulane University Medical Center | Tulane University Medical Center, New Orleans, LA | Tulane University Medical School | Tulane University School of Medicine | Tulane University School of Medicine, Department of Dermatology | Tulane University School of Public Health and Tropical Medicine | Tulane University SOM, New Orleans, LA 70112

Active Ingredients

Drugs in Phase 4 Trials (22)

alidornase alfa (1 trial)

alteplase (Activase) (2 trials)

amlodipine (norvasc) (1 trial)

bazedoxifene (Duavee) (1 trial)

brimonidine (alphagan) (1 trial)

conjugated equine estrogens (1 trial)

dapagliflozin (farxiga) (1 trial)

dronedarone (multaq) (1 trial)

engerix-b (1 trial)

hepatitis a vaccine, inactivated (vaqta) (1 trial)

hepatitis b vaccine (recombinant) (recombivax) (1 trial)

hydralazine (apresoline) (1 trial)

hydrochlorothiazide (esidrix) (1 trial)

insulin lispro (humalog) (1 trial)

liraglutide (victoza) (1 trial)

live attenuated varicella vaccine (1 trial)

metronidazole (flagyl) (2 trials)

retapamulin (altabax) (1 trial)

sodium chloride (1 trial)

sufonylurea (1 trial)

terazosin (hytrin) (1 trial)

testosterone (delatestryl) (1 trial)

Drugs in Phase 3 Trials (34)

acetylcysteine (mucomyst) (1 trial)

anti-inhibitor coagulant complex (activated prothrombin complex concentrate) (Autoplex-T) (1 trial)

asparaginase (elspar) (1 trial)

benznidazole (Rochagan) (1 trial)

blood plasma (1 trial)

cytarabine (cytosar-u) (1 trial)

darolutamide (Nubeqa) (1 trial)

dextrose (1 trial)

docetaxel (taxotere) (2 trials)

doxorubicin (Doxil) (1 trial)

efavirenz (sustiva) (1 trial)

enzalutamide (xtandi) (2 trials)

foscarnet (foscavir) (1 trial)

ganciclovir (cytovene) (1 trial)

goserelin (zoladex) (1 trial)

imatinib (gleevec) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

leucovorin (1 trial)

leuprolide (lupron) (1 trial)

lidocaine (xylocaine) (1 trial)

lopinavir (Kaletra) (2 trials)

naltrexone (revia) (1 trial)

potassium (1 trial)

prednisone (meticorten) (4 trials)

radium-223 (xofigo) (1 trial)

ritonavir (Norvir) (2 trials)

rituximab (rituxan) (2 trials)

salsalate (salflex) (2 trials)

saxagliptin (onglyza) (1 trial)

sildenafil (viagra) (1 trial)

sitagliptin (januvia) (1 trial)

urea (3 trials)

vincristine (oncovin) (1 trial)

warfarin (coumadin) (1 trial)

Drugs in Phase 2 Trials (32)

4-demethyl-4-cholesteryloxycarbonylpenclomedine (5 trials)

abiraterone (zytiga) (1 trial)

apremilast (otezla) (1 trial)

aq-13 (3 trials)

avelumab (bavencio) (1 trial)

carbon monoxide (1 trial)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

coartem (1 trial)

cycloserine (seromycin) (2 trials)

dexamethasone (1 trial)

didanosine (videx) (1 trial)

elotuzumab (empliciti) (1 trial)

estradiol (progynon depot) (1 trial)

f-652 (1 trial)

Fluciclovine (Axumin) (1 trial)

Galactose (1 trial)

gemcitabine (gemzar) (1 trial)

ghrp-3 (1 trial)

gvax lung cancer vaccine (1 trial)

ifosfamide (ifex) (1 trial)

lumefantrine (Coartem) (1 trial)

nevirapine (viramune) (1 trial)

oxygen (1 trial)

paclitaxel (taxol) (1 trial)

progesterone (progestasert) (1 trial)

qgc001 (1 trial)

rutoside (1 trial)

sargramostim (leukine) (1 trial)

selinexor (Xpovio) (1 trial)

sodium nitrite (1 trial)

zidovudine (retrovir) (1 trial)

Drugs in Phase 1 Trials (13)

amodiaquine (camoquin) (1 trial)

bimatoprost (lumigan) (1 trial)

calcipotriene (dovonex) (1 trial)

chloroquine (1 trial)

dihydroartemisinin (1 trial)

fluorouracil (efudex) (1 trial)

human coagulation factor ix (Mononine) (1 trial)

lactobacillus reuteri (3 trials)

panobinostat (farydak) (1 trial)

piperaquine (1 trial)

pyrimethamine (daraprim) (1 trial)

succinylestriol (1 trial)

sulfadoxine (1 trial)

Drugs in Other Trials (13)

68ga-psma (1 trial)

acetic acid (vosol) (1 trial)

COVID-19 convalescent plasma (1 trial)

dihydroqinghaosu (1 trial)

etomidate (amidate) (1 trial)

inactivated influenza vaccine (1 trial)

magnesium sulfate (Tis-U-Sol) (1 trial)

methylene blue (proveblue) (1 trial)

mizkan rice vinegar (1 trial)

piperaquinoline (1 trial)

propofol (diprivan) (1 trial)

sapropterin (kuvan) (1 trial)

sodium fluoride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 3)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Chagas Disease (Phase 3)

Communicable Diseases (Phase 4)

Congenital Disorders of Glycosylation (Phase 2)

Cutis Laxa (Phase 1)

Cytomegalovirus Retinitis (Phase 3)

Dermatomyositis (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Disease (Phase 2)

Empyema (Phase 4)

Fibrosis (Phase 3)

Glaucoma (Phase 4)

Glaucoma, Open-Angle (Phase 4)

Hemophilia A (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis C (Phase 3)

Herpes Zoster (Phase 4)

HIV Infections (Phase 3)

Hypertension (Phase 4)

Hypertension, Pulmonary (Phase 3)

Idiopathic Pulmonary Fibrosis (Phase 3)

Immunologic Deficiency Syndromes (Phase 3)

Infections (Phase 4)

Inflammation (Phase 3)

Insulin Resistance (Phase 2)

Keratosis (Phase 1)

Keratosis, Actinic (Phase 1)

Kidney Diseases (Phase 2)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Lung Diseases (Phase 3)

Lung Neoplasms (Phase 2)

Malaria (Phase 2)

Malaria, Falciparum (Phase 1)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Overweight (Phase 2)

Pleural Diseases (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Prostatic Neoplasms (Phase 3)

Pulmonary Fibrosis (Phase 3)

Purpura (Phase 3)

Purpura, Thrombocytopenic (Phase 3)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Purpura, Thrombotic Thrombocytopenic (Phase 3)

Renal Insufficiency, Chronic (Phase 2)

Retinitis (Phase 3)

Staphylococcal Infections (Phase 4)

Stress Disorders, Post-Traumatic (Phase 2)

Stress Disorders, Traumatic (Phase 2)

Trichomonas Infections (Phase 4)

Trichomonas Vaginitis (Phase 3)

Ureteral Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Vaginitis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 77
  • # of Trial APIs: 114